Status:
NOT_YET_RECRUITING
Cannabis and Processing Emotions Study
Lead Sponsor:
Auburn University
Collaborating Sponsors:
Society of Addiction Psychology
National Institute on Drug Abuse (NIDA)
Conditions:
Cannabis Use Disorder, Severe
Eligibility:
All Genders
18-50 years
Phase:
NA
Brief Summary
The goal of this study is to test a causal neural mechanism of cannabis use-related problem recognition in individuals with severe cannabis use disorder using a non-invasive form of neuromodulation ca...
Eligibility Criteria
Inclusion
- Meets criteria for current, severe Cannabis Use Disorder (CUD), as assessed by the Structured Clinical Interview (SCID) for the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) during the screening interview
- Reports engagement in cannabis use at least four days per week, on average, over the past year
- Provide a urine sample positive for tetrahydrocannabinol (THC)
- Able to read and write in English
- Has used cannabis at least 20 days in the past month
- Endorses at least 10 distinct (of 40 possible) cannabis use-related problems across the screening interview and Lab Visit 1 questionnaires
Exclusion
- Other non-cannabis illicit substance use more than once per month, on average, over the past year
- Current DSM-5 moderate or severe Alcohol Use Disorder, as assessed by the Structured Clinical Interview (SCID) for the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) during the screening interview
- History of bipolar I or psychosis spectrum disorders, as assessed by the SCID for DSM-5 during the screening interview
- Acute suicidality requiring treatment escalation, as assessed during the screening interview
- Currently taking any daily psychotropic medication
- Failure to meet standard MRI inclusion criteria (i.e., no presence of claustrophobia; cardiac pacemakers; neural pacemakers; surgical clips in the brain or blood vessels; surgically implanted metal plates, screws, or pins; cochlear implants; implanted uterine devices; metal braces; other metal objects in the body; history of significant injury to the brain or spinal cord; or pregnancy)
- Medical contraindications for transcranial magnetic stimulation (TMS; i.e., presence of a neurological disorder known to alter risk for seizures \[e.g., stroke, aneurysm, brain surgery, structural brain lesion, brain injury, frequent/severe headaches\], current medication therapy known to alter seizure threshold \[e.g., clomipramine, Monoamine Oxidase inhibitors, imipramine, clozapine\], recurrent seizures or epilepsy or family history of hereditary epilepsy, pregnancy, metallic implants in the body or other devices that may be affected by magnetic fields, or significant heart disease or cerebrovascular disease)
- History of allergies to cosmetics/lotions or EEG gel
- History of migraines
- Currently engaged in treatment for Cannabis Use Disorder
Key Trial Info
Start Date :
January 1 2026
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2027
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT06907979
Start Date
January 1 2026
End Date
May 1 2027
Last Update
November 10 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.